▲ Peaking
Business
Why the FDA should not approve an ineffective multicancer screening test
FDA approval of ineffective multicancer screening test sparks debate
Biotech
71 independently detected trends connected to this subject, with the latest coverage first.
What Archynetys tracks about Biotech
This hub groups 71 separate news trends connected to Biotech, spanning June 23, 2026 through October 7, 2026. Each event page combines source coverage, attention velocity and a time-stamped explanation instead of treating every headline as a separate story.
The record below represents 578 article observations and 537 source signals, led by Business, Health, Science coverage. Use it to compare how individual events emerged, spread and changed over time.
▲ Peaking
Business
🔮 fades
Astra Doesn’t Need a Deal for Growth Beyond 2030, CEO Says
8 news sources are covering this Business story right now — Archynetys is tracking how fast it spreads.
▲ Peaking
Business
🔮 fades ✓
Vaxcyte’s stock jumps as pneumococcal vaccine holds its own against Pfizer's, Merck’s shots
Vaxcyte’s VAX‑31 Phase 3 win sparks a 36% rally, thrusting the small biotech into direct competition with Pfizer and Merck in the $7 billion pneumococcal market.
↑ Rising
Business
🔮 fades ✓
Introducing Fierce Biotech's 2026 Fierce 15
Fierce Biotech names top 15 biotech companies of 2026.
◼ Archived
Business
🔮 fades ✓
Beam sues YolTech and Serapha Bio for allegedly stealing its gene editing tech
Gene editing tech at the center of a high-stakes lawsuit.
◼ Archived
Business
🔮 fades ✓
Adicet Bio CAR-T sparks lupus remissions in early trial as ‘new era’ of autoimmune treatment approaches
5 news sources are covering this Business story right now — Archynetys is tracking how fast it spreads.
◼ Archived
Technology
🔮 fades ✓
AI co-scientists are revolutionizing how research is done
5 news sources are covering this Technology story right now — Archynetys is tracking how fast it spreads.
◼ Archived
Business
🔮 fades ✓
Biotech's most exciting startups of 2026: Meet this year's Endpoints 11
5 news sources are covering this Business story right now — Archynetys is tracking how fast it spreads.
◼ Archived
Business
🔮 fades ✓
FDA panel endorses first-of-a-kind cancer blood test from Grail
FDA panel endorses first-of-a-kind cancer blood test from Grail, but controversy lingers.
◼ Archived
Business
🔮 fades ✓
Nvidia-backed Iambic files for IPO, disclosing new clinic and dealmaking details
Nvidia-backed Iambic Therapeutics' IPO filing surprises with disclosed clinic and dealmaking details amid a biotech IPO surge
◼ Archived
Business
🔮 fades ✓
Novartis secures new radioligand in $900M deal as competition strengthens
Novartis’s $900 million BoomRay radioligand deal spotlights a China-origin, preclinical asset amid mounting competition in the biotech field
◼ Archived
Business
🔮 fades ✓
Exclusive
20 news sources are covering this Business story right now — Archynetys is tracking how fast it spreads.
◼ Archived
Business
🔮 fades ✓
Grail Catapults 30%-Plus As FDA Mulls Cancer-Detecting Blood Test
FDA's evaluation of Grail's cancer-detecting blood test sparks market optimism
◼ Archived
Business
🔮 fades ✓
Updated: Electra says $350M IPO will help it become a commercial biotech
9 news sources are covering this Business story right now — Archynetys is tracking how fast it spreads.
◼ Archived
Business
🔮 fades ✓
EXCLUSIVE: US weighs allowing most pharma licensing deals with China, sources say
5 news sources are covering this Business story right now — Archynetys is tracking how fast it spreads.
◼ Archived
Science
🔮 fades ✓
Virtual biotech company puts thousands of AI scientist agents to work on drug discovery
Virtual biotech company deploys thousands of AI scientist agents for drug discovery.
◼ Archived
Health
🔮 fades ✓
Pandemic Preparation is AI Safety
10 news sources are covering this Health story right now — Archynetys is tracking how fast it spreads.
◼ Archived
Business
🔮 fades ✓
Novo explores macrocycles’ potential in $1.4B cardiometabolic pact with Danish biotech
Novo Nordisk has signed an up to $1.4 billion licensing deal with Danish biotech Orbis Medicines to develop oral macrocycle drugs for cardiometabolic diseases.
◼ Archived
Business
🔮 fades ✓
Montana’s giving the biotech industry sweeping authority to sell unapproved drugs
4 news sources are covering this Business story right now — Archynetys is tracking how fast it spreads.
◼ Archived
Business
🔮 fades ✓
Experts urge FDA to set clear safety and access standards for psychedelic drugs
A September 14 FDA hearing pushes psychedelic drug standards to the forefront as veterans and the public demand faster access.
◼ Archived
Business
🔮 fades ✓
Could Western Mass be to food’s future what Boston is to biotech? UMass is betting on it with $120 million.
$120 million initiative aims to transform Western Mass food industry
◼ Archived
Business
🔮 fades ✓
Roivant’s $14M bet on Bayer’s inhaled hypertension med pays off with phase 2 win
Roivant's experimental lung disease drug meets phase 2 goals
◼ Archived
Business
🔮 fades ✓
Early Data Indicates an A.I.-Generated Drug Could Slow Aging
Early data suggests an AI-generated drug may slow aging, sparking hopes for a breakthrough in human longevity.
◼ Archived
Business
🔮 fades ✓
She lost her sight. Her billionaire father bet on a daring new treatment.
Bill Ackman's bold gamble on a mitochondrial eye transplant for his blind daughter thrust experimental vision therapy into the spotlight
◼ Archived
Business
🔮 fades ✓
Teva autoimmune antibody notches ph. 2 win in celiac disease
Teva's experimental antibody TEV-408 hits a key phase IIa endpoint in celiac disease studies.
◼ Archived
Business
🔮 fades ✓
Novartis inks $3.2B subcutaneous delivery deal with Alteogen
Novartis secures a high-stakes subcutaneous delivery agreement with Alteogen, shifting industry dynamics and drawing varied market reactions.
◼ Archived
Business
🔮 fades ✓
ARPA-H awards $125M for manufacturing custom RNA therapies on demand
The US government is investing heavily in on-demand RNA therapies, but the path to market is not straightforward.
◼ Archived
Business
🔮 fades ✓
Novartis Just Broke Out, Again, As Its Roche Rivalry Heats Up
Two positive Phase III results for an oral multiple sclerosis drug have pushed Novartis forward in a competitive pharmaceutical market.
◼ Archived
Business
Lilly snags another Massachusetts biotech as local headcount surges past 1,400
Eli Lilly's $2.88 billion bid for Merida Biosciences marks its 13th 2026 acquisition, swelling Massachusetts biotech staffing.
◼ Archived
Business
🔮 fades ✓
Eli Lilly inks $2.88B Merida buyout for autoimmune drugs against rogue antibodies
Eli Lilly's $2.88 billion acquisition of Merida Biosciences is poised to reshape the autoimmune disease treatment landscape.
◼ Archived
Business
🔮 fades ✓
Trump reportedly plans to announce new drug pricing deals with nearly a dozen drugmakers
Nearly a dozen drug deals promise $600 billion in savings for American patients.
◼ Archived
Business
BioNTech-Genentech cancer vax records more deaths than control in scrapped ph. 2 test
BioNTech and Roche have halted a mid-stage cancer vaccine trial after more deaths occurred in the treatment group than in the control group.
◼ Archived
Business
🔮 fades ✓
China is a Threat to Biotech’s Massive Bull Run
Congress pushes a China‑targeted biotech shield even as the sector rides a historic bull run.
◼ Archived
Business
🔮 fades ✓
Founded by Metsera backers, Sentivera emerges with $1.5B inflammatory disease deal
A $1.5 billion China‑U.S. biotech pact puts American VCs and Haisco at the center of a new inflammatory‑disease platform.
◼ Archived
Business
🔮 fades ✓
Bristol Myers ends deal with Cellares, cell therapy manufacturer to reorg
Bristol Myers Squibb ends blood‑cancer deal, prompting Cellares to cut 100 jobs and reorganize.
◼ Archived
Business
🔮 fades ✓
Vacant lab space, shrinking workforce put Mass. in ‘unique position’ for biotech bounceback
Massachusetts' biotech sector faces a paradox: job losses amid a rebound in investment.
◼ Archived
Business
🔮 fades ✓
Roche pens $2.5B pact for Hanmi’s clinical-stage obesity drug targeting less-explored mechanism
Roche’s $2.5 billion pact for Hanmi’s muscle‑sparing obesity drug ignites expectations for a new weight‑loss breakthrough
◼ Archived
Health
🔮 fades ✓
NUS researchers find drug that turns off ‘master switch’ in aggressive breast cancer
6 news sources are covering this Health story right now — Archynetys is tracking how fast it spreads.
◼ Archived
Business
🔮 fades ✓
Moderna, Merck breakthrough could usher in wave of cancer vaccines
A cancer vaccine breakthrough is stirring debate over profits and public health, as Moderna and Merck's stock prices surge.
◼ Archived
Business
🔮 fades ✓
Moderna Shares Double on Success of mRNA Cancer Vaccine
Moderna's shares have doubled since August 19th, 2026, as investors react to a breakthrough in cancer treatment.
◼ Archived
Business
Amylyx Stock Surges 55% After GLP-1 Blocker Hits All Trial Goals
Amylyx stock surged 55% after its GLP-1 blocker drug met all trial goals
◼ Archived
Health
🔮 fades ✓
A pill that mimics exercise? Early results on drug designed to maintain both weight loss and muscle mass
A drug designed to mimic exercise has passed its first human test, sparking interest in the medical community.
◼ Archived
Business
🔮 fades ✓
A New Use for GLP-1s? Amylyx Pharma Catapults To 3-Year High
Amylyx Pharmaceuticals' stock surges after a GLP-1 antagonist drug shows promise in a new application.
◼ Archived
Health
🔮 fades ✓
Chinese team aims to put ‘smart’ diabetes probiotic on US shelves within 2 years
A Chinese team is racing to bring a 'smart' probiotic for diabetes to the US market.
◼ Archived
Business
🔮 fades ✓
The Surprising Reason This Biotech Plummeted 69%
EyePoint Pharmaceuticals' stock plummets after a clinical trial setback, leaving investors reeling and analysts divided.
◼ Archived
Health
🔮 fades ✓
How to build an AI-driven digital organism
Scientists are racing to build AI-driven digital organisms to test drugs before human trials
◼ Archived
Business
🔮 fades ✓
Capricor Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Capricor Therapeutics' stock surges on news of a potential FDA lifeline for its Duchenne muscular dystrophy drug.
◼ Archived
Business
🔮 fades ✓
RK Mellon Foundation pledges $25M to launch rare disease therapy hub in Pittsburgh - Pittsburgh Post-Gazette
The RK Mellon Foundation's $25M investment aims to transform Pittsburgh into a hub for rare disease therapies.
◼ Archived
Business
🔮 fades ✓
Deerfield-backed Boulevard Bio embarks on ‘beautiful path to a cure’ with trio of immunology drugs
Boulevard Bio debuts with $65 million in funding to advance a pipeline of targeted antibody therapies focused on autoimmune disease.
◼ Archived
Business
🔮 fades ✓
AI brings savings to clinical trials: study
Research indicates AI integration could deliver 82 times the return on investment in oncology clinical trials while reshaping the drug development market.
◼ Archived
Business
🔮 fades ✓
Regeneron backs $75M series A for antibody upstart Infinimmune
Alameda-based biotech Infinimmune has secured $75 million in Series A funding to advance its antibody pipeline for atopic dermatitis and inflammatory diseases.
◼ Archived
Health
🔮 fades ✓
Triple-dose regimen may permanently clear HIV in infected newborns
Since August 10, 2026, a triple-dose regimen has shown promise in permanently clearing HIV in infected newborns.
◼ Archived
Business
🔮 fades ✓
This Biotech’s Drug Could Treat Hot Flashes. The Stock Is Up 34% on Good News.
AbCellera's stock surged after its drug showed promise in treating menopause hot flashes.
◼ Archived
Business
🔮 fades ✓
‘Greg, you’ve got to bring back this platform’: How LifeMine won over Gates and Bezos for $188M series E
LifeMine Therapeutics has secured a massive investment from tech giants Bill Gates and Jeff Bezos, despite conflicting reports on the amount raised.
◼ Archived
Science
🔮 fades ✓
Gene-edited beagles may offer a future option for people with dog allergies
Kindred Companion Sciences has unveiled the world's first beagles genetically edited via CRISPR to remove the protein responsible for triggering dog allergies.
◼ Archived
Business
🔮 holds ✗
FDA Panel Votes In Favor of Replimune’s Melanoma Treatment
An FDA advisory committee has voted 10-3 in favor of Replimune’s oncolytic immunotherapy for melanoma, marking a turning point for the twice-rejected treatment.
◼ Archived
Business
🔮 fades ✓
MapLight shares sink on mixed ph. 2 schizophrenia readout
7 news sources are covering this Business story right now — Archynetys is tracking how fast it spreads.
◼ Archived
Business
🔮 fades ✓
FDA staff flags data concerns about Capricor's therapy; shares plunge
Capricor Therapeutics shares are plunging after FDA staff disputed the company's claims regarding Phase 3 success for its DMD cell therapy.
◼ Archived
Business
🔮 holds ✗
Argenx to Buy Forte Biosciences for $2.2 Billion
8 news sources are covering this Business story right now — Archynetys is tracking how fast it spreads.
◼ Archived
Business
🔮 fades ✗
The 'Surprisingly Soft' Unit That Caused Danaher To Plummet
Danaher shares are sliding despite a second-quarter earnings beat and raised guidance, driven by a "surprisingly soft" business unit.